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Striatal-enriched protein tyrosine phosphatase (STEP) is highly expressed in striatal projection neurons, the neuronal population most
affected in Huntington’s disease. Here, we examined STEP expression and phosphorylation, which regulates its activity, in N-terminal
exon-1 and full-length mutant huntingtin mouse models. R6/1 mice displayed reduced STEP protein levels in the striatum and cortex,
whereas its phosphorylationwas increased in the striatum, cortex, andhippocampus. The early increase in striatal STEPphosphorylation
levels correlatedwith aderegulationof theproteinkinaseApathway, anddecreased calcineurin activity at later stages further contributes
to an enhancement of STEP phosphorylation and inactivation. Accordingly, we detected an accumulation of phosphorylated ERK2 and
p38, two targets of STEP, in R6/1mice striatum at advanced stages of the disease. Activation of STEP participates in excitotoxic-induced
cell death.BecauseHuntington’sdiseasemousemodelsdevelop resistance to excitotoxicity,weanalyzedwhetherdecreasedSTEPactivity
was involved in this process. After intrastriatal quinolinic acid (QUIN) injection, we detected higher phosphorylated STEP levels in R6/1
than in wild-type mice, suggesting that STEP inactivation could mediate neuroprotection in R6/1 striatum. In agreement, intrastriatal
injectionofTAT–STEP increasedQUIN-inducedcell death.R6/2, Tet/HD94, andHdhQ7/Q111mice striatumalsodisplayeddecreasedSTEP
protein and increased phosphorylation levels. In Tet/HD94 mice striatum, mutant huntingtin transgene shutdown reestablished STEP
expression. In conclusion, the STEP pathway is severely downregulated in the presence of mutant huntingtin and may participate in
compensatory mechanisms activated by striatal neurons that lead to resistance to excitotoxicity.
Introduction
Striatal-enriched protein tyrosine phosphatase (STEP), encoded
by the Ptpn5 gene, is a brain-specific phosphatase involved in
neuronal signal transduction. STEP is enriched in the striatum
(Lombroso et al., 1991) and expressed at lower levels in the cor-
tex, hippocampus, and amygdala (Boulanger et al., 1995). STEP
mRNA is alternatively spliced into the membrane-associated
STEP61 and the cytosolic STEP46 (Bult et al., 1997). Both isoforms
are expressed in the striatum, whereas the hippocampus and cor-
tex only express STEP61 (Boulanger et al., 1995).
STEP activity is regulated through phosphorylation/dephos-
phorylation of a serine residue within its kinase interacting motif
domain. Stimulation of dopamine D1 receptors (D1Rs) activates
the cAMP-dependent protein kinase A (PKA) (Stoof and Keba-
bian, 1981), which phosphorylates STEP46 and STEP61, thereby
inactivating them (Paul et al., 2000). In contrast, glutamate stim-
ulation of NMDA receptors (NMDARs) results in the dephos-
phorylation and activation of STEP through a calcineurin/PP1
pathway (Paul et al., 2003; Valjent et al., 2005). Once activated,
STEP dephosphorylates the glutamate receptor subunits NR2B
(Pelkey et al., 2002; Snyder et al., 2005; Braithwaite et al., 2006)
and GluR2 (Zhang et al., 2008), leading to their endocytosis, and
the kinases ERK1/2 (extracellular signal-regulated kinase 1/2),
p38, and Fyn, thereby controlling the duration of their signal
(Pulido et al., 1998; Nguyen et al., 2002; Mun˜oz et al., 2003; Paul
et al., 2003).
Striatal projection neurons are specially affected in Hunting-
ton’s disease (HD) (Reiner et al., 1988), a dominantly inherited
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neurodegenerative disorder caused by an abnormal expansion of
a CAG codon in exon-1 of the huntingtin (htt) gene (The Hun-
tington’s Disease Collaborative Research Group, 1993). The en-
richment of STEP in these neurons, together with its role in the
regulation of key substrates implicated in neuronal function, sug-
gest that STEP may play a role in the pathophysiology of HD. In
fact, previous studies show decreased mRNA levels of STEP in the
caudate nucleus and cortex of HD patients (Hodges et al., 2006)
and in the striatum of R6 mice (Luthi-
Carter et al., 2000; Desplats et al., 2006).
Moreover, both dopaminergic and gluta-
matergic systems, which regulate STEP
activity, are affected in HD patients and
mouse models (Jakel and Maragos, 2000;
Fan and Raymond, 2007; Andre´ et al.,
2010).
Excitotoxicity has been proposed to
contribute to the selective loss of striatal
projection neurons in HD (for review, see
Pe´rez-Navarro et al., 2006; Fan and Ray-
mond, 2007). However, mouse models of
HD develop resistance to excitotoxicity
(Hansson et al., 1999, 2001; Jarabek et al.,
2004; Torres-Peraza et al., 2008; Graham
et al., 2009), and we have shown previ-
ously that reduced levels of calcineurin ex-
pression and activity could participate in
this phenomenon (Xifro´ et al., 2009). In-
terestingly, disruption of STEP activity
leads to the activation of ERK1/2 signaling
and attenuates excitotoxic-induced cell
death in the hippocampus (Choi et al.,
2007). Thus, in the present study, we
sought to investigate STEP protein ex-
pression and activity in several mouse
models of HD and to analyze whether
STEP acts downstream of calcineurin to
regulate cell survival after a striatal excito-
toxic lesion.
Materials andMethods
HD mouse models. Wild-type (WT) HdhQ7/Q7
and heterozygous mutant HdhQ7/Q111 knock-in
mice (C57BL/6 background) were obtained from
matings between male and female HdhQ7/Q111
heterozygous mice as described previously
(Wheeler et al., 1999). R6/1 and R6/2 heterozy-
gous transgenic mice (B6CBA background) ex-
pressing exon-1 mutant huntingtin (mhtt) with
145 (Giralt et al., 2009) and 115 CAG repeats,
respectively, were obtained from The Jackson
Laboratory. Conditional Tet/HD94 mice (CBA
C57BL/6 background) express a chimeric
mouse/human exon-1 mhtt with 94 CAG re-
peats under the control of the bidirectional
tetO responsive promoter (Yamamoto et al.,
2000). To turn off mhtt expression, 17-month-
old wild-type and Tet/HD94 mice were treated
with doxycycline in drinking water during 5
months (2 mg/ml for 4 months, followed by 0.5
mg/ml for 1 month; gene-OFF group) (Díaz-
Herna´ndez et al., 2005). Some animals were left
without intervention (gene-ON group). All
mice used in the present study were housed
together in numerical birth order in groups of
mixed genotypes, and data were recorded for analysis by microchip
mouse number. Experiments were conducted in a blind-coded manner
with respect to genotype. R6 and Tet/HD94 mice were genotyped by PCR
as described previously (Mangiarini et al., 1996; Yamamoto et al., 2000).
Knock-in mice were genotyped by a two-way PCR using the primer pairs
Hdh Up (5 CCT GGA AAA GCT GAT GAA GG) and Hdh Down (5
TGG ACA GGG AAC AGT GTT GC 3) for wild-type htt and CAG1
(5ATG AAG GCC TTC GAG TCC CTC AAG TCC TTC 3) and HU3
Figure 1. STEP protein andmRNA levels are decreased in the striatumof R6/1mice. STEP protein levels (A,B) were analyzed by
Western blot of protein extracts obtained from the striatum of WT and R6/1 mice at different stages of the disease progression
(from4 to 30weeks of age).A,B, Representative immunoblots show the protein levels of STEP61, STEP46, and-tubulin inWT and
R6/1 mice at 4, 8, and 30 weeks of age. The graphs show the decrease in striatal STEP61 (A) and STEP46 (B) protein levels in R6/1
mice with respect to their littermate controls at different stages of the disease progression. Values (obtained by densitometric
analysis of Western blot data) are expressed as percentage of WTmice (STEP61 or STEP46/-tubulin ratio) and shown as mean
SEM (n 9). C, Graph showing STEP mRNA levels analyzed by Q-PCR in the striatum of 8- and 20-week-old WT and R6/1 mice.
Resultswere normalized to the 18S gene expression, expressed as percentage ofWT values, and shown asmean SEM (n 5–7
for each genotype). Data were analyzed by Student’s t test. **p 0.01 and ***p 0.001 compared with WTmice.
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(5 GGC GGC TGA GGA AGC TGA GGA 3)
for mhtt. The animals were housed with ac-
cess to food and water ad libitum in a colony
room kept at 19 –22°C and 40 –50% humid-
ity, under a 12 h light/dark cycle. All animal-
related procedures were in accordance with
the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and
approved by the local animal care committee
of the Universitat de Barcelona (99/01) and
the Generalitat de Catalunya (99/1094).
Total protein extraction. The animals were
deeply anesthetized and killed by decapitation
at the age of 4, 8, 12, 20, or 30 weeks (wild-type
and R6/1), 12 weeks (wild-type and R6/2), 8
months (HdhQ7/Q7 and HdhQ7/Q111 knock-in
mice), or 22 months (wild-type, gene-ON, and
gene-OFF Tet/HD94 mice). Quinolinic acid
(QUIN)-lesioned mice were killed 1 or 4 h after
QUIN injection. The brain was quickly
removed, and the striatum, cortex, and hip-
pocampus were dissected out and homoge-
nized in lysis buffer containing 1% Triton
X-100, 50 mM Tris-HCl, pH 7.5, 10 mM EGTA,
150 mM NaCl, protease inhibitors (2 mM phe-
nylmethylsulphonyl fluoride, 10 g/l apro-
tinin, and 1g/l leupeptin), and phosphatase
inhibitors (2 mM Na3VO4 and 100 mM NaF).
Samples were centrifuged at 16,100 g for 20
min at 4°C, the supernatants were collected,
and the protein concentration was determined
using the Dc protein assay kit (Bio-Rad).
Western blot analysis. Proteins were dena-
tured in 62.5 mM Tris-HCl, pH 6.8, 2% (w/v)
SDS, 10% glycerol, 140 mM -mercaptoethanol,
and 0.1% (w/v) bromophenol blue, heated at
100°C for 5 min, and resolved in denaturing poly-
acrylamide gels. For pNR1 (Ser897) analysis, the
samples were denatured in a 170 mM phosphate
buffer, pH 7, with 2.5% (w/v) SDS, 10% glycerol,
3.2 mM dithiothreitol, and 0.1% (w/v) bro-
mophenol blue. Proteins were transferred to ni-
trocellulose membranes (Whatman Schleicher &
Schuell) and washed twice in Tris-buffered
saline containing 0.1% Tween 20 (TBS-T).
After blocking (TBS-T solution plus 5% bo-
vine serum albumin and 5% skimmed milk) at
room temperature for 1 h, the membranes
were blotted overnight at 4°C with the follow-
ing primary antibodies: anti-STEP (23E5;
1:1000) and anti-phosphoERK2 (pERK) (Tyr204; 1:1000) from Santa
Cruz Biotechnology); anti-panERK (1:5000), anti-p-p38, anti-p38, and
anti-phospho-dopamine- and cAMP-regulated phosphoprotein-32 kDa
(pDARPP-32) (Thr34; 1:1000) from Cell Signaling Technology; anti-
DARPP-32 (1:1000; BD Biosciences); anti-pNR1 (Ser897; 1:1000; Milli-
pore); and anti-pSTEP (1:1000) (Paul et al., 2003). Incubation with a
mouse monoclonal antibody against -tubulin (1:100,000; Sigma) was
performed to obtain loading controls. After primary antibody incuba-
tion, the membranes were washed with TBS-T and incubated for 1 h at
room temperature with the appropriated horseradish peroxidase-
conjugated secondary antibody (1:2000; Promega), and the reaction was
finally visualized with the Western Blotting Luminol Reagent (Santa
Cruz Biotechnology). Western blot replicates were scanned and quanti-
fied using a computer-assisted densitometric analysis (Gel-Pro Analyzer,
version 4; Media Cybernetics).
Quantitative PCR assay. Total RNA was extracted from 8- and 20-
week-old wild-type and R6/1 striatal samples, and cDNA was synthesized
as described previously (Garcı´a-Martı´nez et al., 2007). The cDNA was
then analyzed by quantitative (Q)-PCR using the following TaqMan
Gene Expression Assays (Applied Biosystems): 18S (Hs99999901_s1)
and STEP (Mm00479063_m1) as described previously (Saavedra et al.,
2010). The data were analyzed and quantified using the Comparative
Quantitation Analysis program of the MxProTM Q-PCR analysis soft-
ware version 3.0 (Stratagene) with the 18S gene expression as internal
loading control. Results were expressed as percentage of wild-type values.
Pharmacological treatments and excitotoxic lesion. Wild-type mice (12-
week-old) were injected intraperitoneally with FK-506 (5 mg/kg; dis-
solved in cremophor; Sigma) or vehicle (cremophor) and killed 2.5 h
later. Papaverine (30 mg/kg; dissolved in water; Sigma) or vehicle (water)
was injected intraperitoneally into 12-week-old wild-type mice, and an-
imals were killed by decapitation 10 min after injection. The striatum was
removed and stored at 80°C until being processed for protein extrac-
tion and Western blot analysis as above. QUIN was intrastriatally in-
jected at the following coordinates relative to bregma: anteroposterior
(AP), 0.6 mm; mediolateral (ML), 2 mm; and 2.7 mm below the
dural surface with the incisor bar at 3 mm above the interaural line in
12-week-old (see Fig. 5, 10 nmol) and 25  3-week-old [see Fig. 7, 20
nmol and supplemental Fig. 3, 10 nmol (available at www.jneurosci.org
Figure2. A,B, STEPphosphorylation is increased in the striatumofR6/1mice. pSTEP61 (A) andpSTEP46 (B) levelswereanalyzed
byWestern blot of protein extracts obtained from the striatum ofWT and R6/1mice at different stages of the disease progression
(from 4 to 30weeks of age). Representative immunoblots show protein levels of pSTEP61, pSTEP46, STEP61, STEP46, and-tubulin
inWTandR6/1mice at 4, 8, and30weeks of age. Thegraphs showstriatal pSTEP levels in R6/1micewith respect to their littermate
controls at different stages of the disease progression. Values (obtained by densitometric analysis of Western blot data) are
expressed as percentage of age-matched WT mice (pSTEP61/STEP61 or pSTEP46/STEP46 ratio after normalization with-tubulin)
and shown as mean SEM (n 4–7). Data were analyzed by Student’s t test. *p 0.05, **p 0.01, and ***p 0.001
compared withWTmice; ##p 0.01 and ###p 0.001 compared with 12-week-old R6/1mice; and p 0.05 compared with
20-week-old R6/1 mice.
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as supplemental material)] mice as described previously (Xifro´ et al.,
2009).
Intrastriatal injection of TAT–STEP or TAT–myc control peptide.We inserted
the trans-activating transduction (TAT) nucleotide sequence (TAC-GGT-
CGT-AAAAAA-CGT-CGT-CAG-CGT-CGT-CGT) at the N terminal of
the STEP46 cDNA, subcloned it in pTrcHis–TOPO expression vector,
and transformed it into Escherichia coli, Top10 (Invitrogen). Six histi-
dines and a myelocytomatosis virus (myc) tag were added to the C
terminus to purify the fusion protein and to track it in vivo, respectively.
Fusion proteins were induced with isopropyl--D-thiogalactopyranoside
and affinity purified. Single bands on Westerns blots with myc and STEP
antibodies were used as an indication of purity. The peptides were syn-
thesized by the core facility at Yale University (New Haven, CT). One
hour before intrastriatal QUIN injection (10 nmol in wild-type mice and
20 nmol in R6/1 mice) in 25 3-week-old mice TAT–STEP or TAT–myc
(both 4 M in 0.5 l) was intrastriatally injected at the following coordi-
nates relative to bregma: AP,0.6 mm; ML,2 mm; and 2.7 mm below
the dural surface with the incisor bar at 3 mm
above the interaural line. To evaluate the pos-
sible toxicity of TAT–STEP, 25  3-week-old
wild-type mice received an intrastriatal injec-
tion of PBS alone or TAT–STEP (4 M in 0.5
l) 1 h before PBS injection.
Fluoro-Jade staining. Twenty-four hours
after intrastriatal QUIN injection, with or with-
out previous TAT-peptide infusion, mice (n
4 –5 for each condition) were deeply anesthe-
tized and immediately perfused transcardially
with saline, followed by 4% paraformaldehyde/
phosphate buffer. Brains were removed and
postfixed for 1–2 h in the same solution, cryo-
protected by immersion in 30% sucrose/PBS,
and then frozen in dry ice-cooled isopentane.
Serial coronal cryostat sections (30m) through
the whole striatum were collected on silane-
coated slides. Striatal sections were processed
for Fluoro-Jade staining (Histo-Chem Inc.) as
described previously (Schmued et al., 1997).
Sections stained with Fluoro-Jade were visual-
ized on a computer, and the border of the
lesion was outlined using the Computer-
Assisted Stereology Toolbox (CAST) software
(Olympus). The volume of the lesion was esti-
mated by multiplying the sum of all the sec-
tional areas (square micrometer) by the
distance between successive sections (240m),
as described previously (Pe´rez-Navarro et al.,
2000).
Immunohistochemistry. Serial coronal sec-
tions (30 m) were obtained as described for
Fluoro-Jade staining and processed for free-
floating immunohistochemistry for myc
and/or pERK2. The sections were washed three
times in PBS and permeabilized/blocked by in-
cubating with PBS containing 0.3% Triton
X-100 and 3% normal goat serum (Pierce) for
15 min at room temperature. After three
washes, the brain slices were incubated over-
night at 4°C under continuous agitation with
mouse anti-myc (1:200) and/or rabbit anti-
pERK2 (1:250), both from Santa Cruz Biotech-
nology, in a PBS with 0.02% sodium azide
buffer. After primary antibody incubation,
slices were washed three times and then incu-
bated 2 h under continuous agitation at room
temperature with cyanine (Cy) 3 goat anti-
mouse or Cy3 goat anti-rabbit for simple im-
munolabeling, or with Cy3 goat anti-rabbit
and Cy2 goat anti-mouse for double labeling
(all 1:300; Jackson ImmunoResearch). No sig-
nal was detected in controls incubated in the absence of the primary
antibody. pERK2 immunoreactivity was quantified using freeware NIH
ImageJ version 1.33 by Wayne Rasband (National Institutes of Health,
Bethesda, MD). Integrated optical density (IOD) values were obtained by
delineating the lesioned and nonlesioned striatal areas.
Statistical analysis. Statistical analysis was performed using the Stu-
dent’s t test or the one- or two-way ANOVA, followed by Bonferroni’s
post hoc test as appropriate and indicated in the figure legends. A 95%
confidence interval was used and values of p  0.05 were considered as
statistically significant.
Results
STEP61 and STEP46 levels are decreased in the striatum of
R6/1 mice
We first analyzed the expression of STEP61 and STEP46 in the
striatum of R6/1 mice to determine whether STEP protein levels
Figure 3. pERK2 and p-p38 levels are increased in the striatum of R6/1mice. pERK2 (A) and p-p38 (B) levels were analyzed by
Western blot of protein extracts obtained from the striatum of 8- to 30-week-oldWT and R6/1mice. Representative immunoblots
showprotein levels of pERK2, ERK2, p-p38, p38, and-tubulin inWTandR6/1mice at 8, 20, and30weeks of age. Thegraphs show
that the striatal levels of pERK2andp-p38are significantly increased inR6/1micewith respect to their littermate controls at 20 and
30weeks of age. Values (obtainedbydensitometric analysis ofWestern blot data) are expressed as percentage of age-matchedWT
mice (pERK2/ERK2 and p-p38/p38 ratio after normalization with -tubulin) and shown as mean SEM (n 6). Data were
analyzed by Student’s t test. *p 0.05, **p 0.01, and ***p 0.001 compared with WTmice.
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were changed in striatal cells expressing
N-terminal exon-1 mhtt. To this end, we
performed Western blot of striatal protein
extracts obtained from 4-, 8-, 12-, 20-, and
30-week-old mice. STEP61 (Fig. 1A) and
STEP46 (Fig. 1B) protein levels were un-
changed in R6/1 mice at 4 weeks of age
compared with wild-type animals. In con-
trast, STEP61 (Fig. 1A) and STEP46 (Fig. 1B)
protein levels were significantly decreased
in the striatum of 8-week-old R6/1 mice, a
reduction that was maintained in 12-, 20-,
and 30-week-old animals.
To determine whether the decrease in
striatal STEP levels was associated with a
downregulation of mRNA expression, we
performed Q-PCR. Consistent with re-
duced STEP protein levels at 8 weeks,
Q-PCR analysis revealed a reduction in
STEP mRNA levels in the striatum of R6/1
mice (50  7% of wild-type levels) (Fig.
1C). A similar decrease in striatal STEP
mRNA levels was found in samples from
20-week-old R6/1 mice (Fig. 1C). These
data indicate that, in the presence of mhtt,
both STEP mRNA and protein levels are
reduced in the striatum, a decrease that is
sustained during the disease progression.
Progressive increase of STEP
phosphorylation in the striatum
of R6/1 mice
Because STEP ability to bind to and dephos-
phorylate its substrates is regulated through
phosphorylation, we looked at pSTEP61 and
pSTEP46 levels to evaluate STEP activity in
R6/1 mice striatum. As shown in Figure 2A,
8- and 12-week-old R6/1 mice showed an
approximately threefold increase in striatal
pSTEP61 levels that progressively increased
at later stages of the disease. In contrast, stri-
atal pSTEP46 levels were only increased in
30-week-old R6/1 mice (Fig. 2B). These re-
sults indicate that STEP phosphorylation
increases with age and suggest that its activ-
ity progressively decreases in the striatum of
R6/1 mice.
Figure4. Regulation ofNR1, DARPP-32, and STEPphosphorylation in the striatum.A,B, Thephosphorylation levels of a specific
PKA residueonNR1 (Ser897) (A) andonDARPP-32 (Thr34) (B)were analyzedbyWesternblot of protein extracts obtained from the
striatum of WT and R6/1 mice at 4, 12, and 30 weeks of age. Representative immunoblots are presented. The graphs show
increased levels of pNR1 (Ser897) (A) and pDARPP-32 (Thr34) (B) in R6/1micewith respect to their littermate controls at different
stages of the disease progression. Values (obtained by densitometric analysis ofWestern blot data) are expressed as percentage of
age-matchedWTmice [pNR1 (Ser897)/NR1 ratio or pDARPP-32 (Thr34)/DARPP-32 ratio after normalization with-tubulin] and
shown asmean SEM (n 8). Data were analyzed by Student’s t test. *p 0.05 and **p 0.01 comparedwithWTmice; and
#p 0.05 compared with 12-week-old R6/1 mice. C, PKA activation or calcineurin inhibition increases pSTEP61 levels in the
striatum. Twelve-week-old WT mice (n 6 for each condition) received an intraperitoneal injection of vehicle, papaverine (30
mg/kg; Papav.), or FK-506 (5mg/kg), and striatal pSTEP61 levelswere analyzed byWestern blot (10min after papaverine and 2.5 h
afterFK-506injection).Representative immunoblots showprotein levelsofpSTEP61, STEP61, and-tubulin inallconditionsexamined.Values
4
(obtained by densitometric analysis of Western blot data) are
expressed as percentage of vehicle-injected mice (pSTEP61 /
STEP61 ratio after normalizationwith-tubulin) and shownas
mean SEM. D, PKA activation, but not calcineurin inhibi-
tion, increases pNR1 (Ser897) levels in the striatum. Twelve-
week-old WT mice (n  6 for each condition) received an
intraperitoneal injectionof vehicle, papaverine (30mg/kg; Pa-
pav.), or FK-506 (5 mg/kg), and striatal pNR1 (Ser897) levels
were analyzed by Western blot. Representative immunoblots
showprotein levels of pNR1 (Ser897) and-tubulin in all con-
ditions examined. Values (obtained by densitometric analysis
of Western blot data) are expressed as percentage of vehicle-
injected mice [pNR1 (Ser897)/-tubulin ratio] and shown as
mean SEM. Data were analyzed by Student’s t test. **p
0.01 and ***p 0.001 comparedwith vehicle-injectedmice.
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Alterations in STEP expression and phosphorylation in R6/1
mice are not restricted to the striatum
To determine whether the reduction of STEP protein levels and
activation was a general mechanism triggered by neurons in re-
sponse to mhtt expression, STEP61 protein and phosphorylation
levels were determined in the cortex and hippocampus of R6/1
mice at different stages of the disease. Although cortical STEP61
levels were decreased, no changes were found in hippocampal
STEP61 protein levels (supplemental Ta-
ble 1, available at www.jneurosci.org as
supplemental material). In contrast, and
as observed in the striatum, cortical and
hippocampal pSTEP61 levels were signifi-
cantly increased in R6/1 mice from 8 to 30
weeks of age (supplemental Table 1, avail-
able at www.jneurosci.org as supplemental
material). Together, these data indicate that,
in the presence of mhtt, STEP protein ex-
pression is regulated in a region-dependent
manner, whereas the effect on STEP phos-
phorylation is more widespread.
Increased STEP phosphorylation in the
striatum of R6/1 mice correlates with
increased pERK2 and p-p38 levels at
late stages of disease progression
If the phosphorylation/inactivation of
STEP in R6/1 mice is physiologically rele-
vant, then STEP targets should be more
phosphorylated in these animals. To ad-
dress this question, we next examined
pERK2 and p-p38 levels in the striatum of
R6/1 mice from 8 to 30 weeks of age. Nei-
ther pERK2 (Fig. 3A) nor p-p38 (Fig. 3B)
levels were significantly altered in 8- or
12-week-old R6/1 mice. In contrast, there
was a significant increase in both pERK2
(Fig. 3A) and p-p38 (Fig. 3B) levels in the
striatum of 20- and 30-week-old R6/1
mice compared with age-matched wild-
type animals. These data support the idea
that the loss of STEP activity is progressive
in R6/1 striatum.
The accumulation of pSTEP correlates
with a deregulation of PKA and
calcineurin pathways in the striatum
of R6/1 mice
The phosphorylation levels of STEP are
regulated by PKA-dependent phosphory-
lation and calcineurin-dependent de-
phosphorylation (Paul et al., 2000, 2003).
Because calcineurin activity in the stria-
tum of R6/1 mice is not reduced until 16
weeks of age (Xifro´ et al., 2009), we exam-
ined whether the increase in pSTEP61 lev-
els observed in the striatum of 8- and 12-
week-old R6/1 mice (Fig. 2A) was
attributable to altered PKA activity. To
address this issue, we analyzed two addi-
tional PKA substrates: (1) the NMDAR
subunit NR1 (Ser897) (Tingley et al.,
1997) and (2) DARPP-32 (Thr34) (Hem-
mings et al., 1984). Striatal NR1 protein levels are not altered in
the striatum of R6/1 mice during the disease progression (Torres-
Peraza et al., 2008), and it is not dephosphorylated by calcineurin
(Lee, 2006). Conversely, like STEP, DARPP-32 mRNA and pro-
tein levels are downregulated in the presence of mhtt (Luthi-
Carter et al., 2000; van Dellen et al., 2000), and it is
dephosphorylated by calcineurin (Halpain et al., 1990). The lev-
els of pNR1 (Ser897) were not altered in the striatum of R6/1 mice
Figure 5. A,B, Regulation of STEP and ERK2 signaling after intrastriatal QUIN injection. pSTEP61 (A) pSTEP46 (B), and pERK2 (C)
levels were analyzed byWestern blot of protein extracts obtained from the striatum of 12-week-old WT and R6/1 mice, 1 and 4 h
after an intrastriatal injection of vehicle or QUIN (10 nmol). Representative immunoblots show protein levels of pSTEP61, STEP61,
and-tubulin (A), pSTEP46, STEP46, and-tubulin (B), and pERK2, ERK2, and-tubulin (C) in WT and R6/1 striatum, 1 and 4 h
after QUIN injection. Values (obtained by densitometric analysis of Western blot data) are expressed as percentage of the con-
tralateral vehicle-injectedWT striatum (pSTEP61/STEP61 ratio, pSTEP46/STEP46 ratio, or pERK2/ERK2 ratio, after normalizationwith
-tubulin), and data shown are the mean SEM (n 7–9). Data were analyzed by two-way ANOVA, followed by Bonferroni’s
post hoc test. *p 0.05, **p 0.01, and ***p 0.001 comparedwith vehicle-injected contralateral WT striatum.WT, Vehicle-
injectedWT striatum;WTQUIN, QUIN-injectedWT striatum; R6/1, vehicle-injected R6/1 striatum; R6/1QUIN, QUIN-injected
R6/1 striatum.
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at 4 weeks of age, whereas we observed a comparable increase
in pNR1 (Ser897) levels in 12- and 30-week-old R6/1 mice
striatum (Fig. 4A). Similarly to pSTEP61 and pNR1 (Ser897),
pDARPP-32 (Thr34) levels were not altered at 4 weeks of age,
whereas its levels were progressively enhanced in the striatum
of R6/1 mice, with the highest increase observed at 30 weeks
of age (Fig. 4B). Because calcineurin dephosphorylates
pDARPP-32 (Halpain et al., 1990) but not pNR1 (Lee, 2006),
these results suggest that the early changes in pSTEP61, pNR1,
and pDARPP-32 levels in the striatum of R6/1 mice are caused
by a deregulation in the PKA pathway, which at later stages
of the disease progression operates together with reduced
calcineurin activity to additionally enhance STEP61 and DARPP-32
phosphorylation.
To explore this possibility, we examined pSTEP61 and
pNR1 (Ser897) levels in wild-type mice after acute modulation
of PKA or calcineurin activity. To activate PKA, we inhibited
phosphodiesterases (PDEs), the enzymes responsible for
cAMP hydrolysis. For that we used papaverine, an inhibitor of
the PDE10A (Siuciak et al., 2006), an isoform that is enriched
in striatal medium spiny neurons (Fujishige et al., 1999; Seeger
et al., 2003; Xie et al., 2006). To inhibit calcineurin activity, we
used FK-506 (Xifro´ et al., 2009). Both papaverine and FK-506
treatment induced an increase in pSTEP61 levels in the stria-
tum of wild-type mice (Fig. 4C). We also observed increased
pNR1 (Ser897) levels after papaverine injection, whereas cal-
cineurin inhibition had no effect on pNR1 (Ser897) levels (Fig.
4D). Altogether, these findings indicate that both PKA and
calcineurin deregulation contribute to enhance STEP phos-
phorylation in the presence of mhtt.
Regulation of STEP and ERK2 signaling after an excitotoxic
stimulus to the striatum
Intrastriatal injection of the NMDAR agonist QUIN has been
extensively used as a model of HD (Schwarcz et al., 2010). We
recently reported that activation of calcineurin promotes QUIN-
induced excitotoxic cell death in the striatum (Xifro´ et al., 2009).
Because the stimulation of NMDARs activates STEP in a
calcineurin-dependent manner (Paul et al., 2003), we next exam-
ined whether STEP acts as a calcineurin target after an excitotoxic
stimulus to the striatum. In wild-type mice, there was a reduction
in pSTEP61 (Fig. 5A) and pSTEP46 (Fig. 5B) levels 1 h after intra-
striatal QUIN injection that returned to control values at 4 h.
These results are consistent with our previous results showing a
twofold increase in calcineurin activity 1 h after intrastriatal
QUIN injection with no differences from nonlesioned striatum at
4 h (Xifro´ et al., 2009). Because STEP61 can be cleaved by calpain
after a rapid influx of Ca 2 during glutamate receptor stimula-
tion leading to the appearance of a lower-molecular-weight inac-
tive isoform, STEP33 (Nguyen et al., 1999; Xu et al., 2009), we
analyzed whether this process occurred in QUIN-injected stria-
tum. We found no changes in STEP61 or STEP33 levels either 1 or
4 h after QUIN injection in wild-type mice striatum (supplemen-
tal Fig. 1, available at www.jneurosci.org as supplemental mate-
rial). Consistent with ERK activation during synaptic NMDAR
stimulation (Ivanov et al., 2006; Le´veille´ et al., 2008; Xu et al.,
2009), 1 h after intrastriatal QUIN injection, there was an in-
crease in pERK2 levels that returned to basal levels at 4 h after
injection (Fig. 5C). In accordance with STEP dephosphorylation
and activation 1 h after QUIN injection, we also observed a re-
duction in p-p38 levels (76  7% compared with the vehicle-
injected side; p 0.0095) that returned to control levels 4 h after
QUIN injection.
R6 mouse models gradually develop resistance to excitotoxicity
induced by QUIN (Hansson et al., 2001), and reduced calcineurin
activity accounts for R6/1 mice resistance to excitotoxicity (Xifro´
et al., 2009). Because our results show a dynamic regulation of
STEP and ERK1/2 activity after intrastriatal QUIN injection in
wild-type animals, we hypothesized that this signaling cascade
could be modified in the presence of exon-1 mhtt and thereby
account for the resistance to excitotoxicity reported in these
animals. Thus, we analyzed pSTEP and pERK2 levels after QUIN
injection in R6/1 mice at 12 weeks of age, when they are resistant
to excitotoxicity. In contrast to that observed in wild-type ani-
mals, in R6/1 mice neither pSTEP61 (Fig. 5A) nor pSTEP46 (Fig.
5B) levels were altered 1 or 4 h after QUIN injection. These results
are consistent with the previous finding that calcineurin activity
after QUIN injection in R6/1 mice is significantly lower than that
observed in wild-type mice and constant between 1 and 4 h after
injection (Xifro´ et al., 2009). No changes in STEP61 or STEP33
levels were found after intrastriatal QUIN injection in R6/1 mice
either (supplemental Fig. 1, available at www.jneurosci.org as
supplemental material). We also observed increased pERK2 lev-
els 1 h after intrastriatal QUIN injection in R6/1 mice, which were
comparable with those registered in wild-type animals (296 
49% compared with wild-type contralateral side). However, in
contrast to wild-type mice, in R6/1 animals pERK2 levels re-
mained significantly elevated 4 h after intrastriatal QUIN injec-
tion (Fig. 5C). These results indicate that, despite a similar
activation of the ERK pro-survival pathway in wild-type and R6/1
mice after intrastriatal QUIN injection, ERK signaling is more pro-
longed in resistant R6/1 than in vulnerable wild-type mice. In con-
trast, p-p38 levels were unchanged 1 and 4 h after intrastriatal QUIN
injection in R6/1 mice (data not shown), a result consistent with no
significant changes in pSTEP levels (Fig. 5A,B).
Our hypothesis was that enhanced activity of the ERK pathway, at
least in part as a result of the lack of STEP activation, may participate
in the reduced neuronal loss observed after QUIN injection in R6/1
mice. To address this possibility, we analyzed pERK2 levels in wild-
Figure6. Inhibition of PDE10Aor calcineurin increases pERK2 levels in the striatum. Twelve-
week-old wild-type mice (n 6 for each condition) received an intraperitoneal injection of
vehicle, papaverine (30 mg/kg; Papav.), or FK-506 (5 mg/kg), and striatal pERK2 levels were
analyzed byWestern blot (10min after papaverine and 2.5 h after FK-506 injection). Represen-
tative immunoblots show protein levels of pERK2, ERK2, and -tubulin in all the conditions
examined. Values (obtained by densitometric analysis of Western blot data) are expressed as
percentageof vehicle-injectedmice (pERK2/ERK2 ratio after normalizationwith-tubulin) and
expressed asmean SEM. Data were analyzed by Student’s t test. *p 0.05 and **p 0.01
compared with vehicle-injected mice.
8156 • J. Neurosci., June 1, 2011 • 31(22):8150–8162 Saavedra et al. • STEP Protein Levels and Activity in HD Models
type mice after treatment with FK-506 or papaverine, because inhi-
bition of calcineurin (Xifro´ et al., 2009) or PDE10A (Giampa` et al.,
2009) prevents QUIN-induced cell death in the striatum. Consistent
with STEP inactivation (Fig. 4C), treatment with papaverine or FK-
506 increased pERK2 levels in the striatum (Fig. 6), thus suggesting
that increased STEP inactivation in R6/1 striatum can mediate
resistance to excitotoxicity through the maintenance of ERK
signaling.
Intrastriatal injection of TAT–STEP peptide increases QUIN-
induced cell death
Older R6/1 mice are more resistant to excitotoxicity than younger
animals (Hansson et al., 2001) and, interestingly, have signifi-
cantly higher striatal levels of phosphorylated/inactive STEP
(Figs. 2, 3). Thus, to directly clarify the relationship between
STEP activity and vulnerability versus resistance to excitotoxic-
ity, we next infused TAT–STEP or TAT–myc in the striatum of
25 3-week-old wild-type and R6/1 mice 1 h before intrastriatal
injection of PBS or QUIN. To confirm that TAT–STEP was taken
up by striatal cells at the moment of QUIN injection, we per-
formed a staining with anti-myc antibody 1 h after TAT–STEP
intrastriatal infusion. As shown in supplemental Figure 2B
(available at www.jneurosci.org as supplemental material), TAT–
STEP was detected in cells surrounding
the site of injection. Intrastriatal injection
of TAT–STEP plus vehicle did not induce
cell death in the striatum of wild-type
mice as assessed by Fluoro-Jade staining
(supplemental Fig. 2C, available at www.
jneurosci.org as supplemental material).
In R6/1 mice striatum, cell death in-
duced by QUIN injection was not mod-
ified by the infusion of the control
peptide TAT–myc (80  16% with re-
spect to QUIN-injected R6/1 striatum)
(Fig. 7Aa2). In contrast, infusion of
TAT–STEP before intrastriatal QUIN
injection increased the volume of the le-
sion compared with that registered in
R6/1 mice receiving the control peptide plus
QUIN injection (308 62% with respect
to QUIN-injected R6/1 striatum; p 
0.0337, Student’s t test) (Fig. 7Aa3). Im-
munohistochemical analysis revealed
that pERK2 levels were decreased (IOD,
63  4% compared with nonlesioned
area; p  0.0027, Student’s t test) in the
striatal region in which cells undergo
cell death (Fig. 7Bb3). Similarly, in wild-
type mice, infusion of TAT–STEP in-
creased the volume of the lesion
compared with that observed in mice re-
ceiving the control peptide plus QUIN
injection (supplemental Fig. 3A,B, available
at www.jneurosci.org as supplemental
material). Furthermore, reduced levels
of pERK2 were detected in striatal cells
localized in the penumbra zone and
containing TAT–STEP (supplemental
Fig. 3C, available at www.jneurosci.org
as supplemental material). These data
demonstrate that STEP increases neuro-
nal vulnerability to excitotoxic stimuli
and further support the involvement of STEP reduced levels
and activity in R6/1 resistance to excitotoxicity.
STEP and pSTEP levels are also modified in the striatum of
R6/2 and HdhQ7/Q111 mice
To investigate whether changes in STEP and pSTEP levels are a com-
mon feature in striatal cells expressing mhtt, we analyzed them in
mice expressing different forms of mhtt: R6/2 mice, which express
N-terminal exon-1 mhtt and show earlier onset and more severe
symptoms than R6/1 mice (Mangiarini et al., 1996), and knock-in
HdhQ7/Q111 mice that show late onset and slow progression of the
disease (Wheeler et al., 1999). As observed in the striatum of R6/1
mice, STEP61 and STEP46 levels were reduced in 12-week-old R6/2
(Fig. 8A) and 8-month-old HdhQ7/Q111 (Fig. 8B) mice. Addition-
ally, both R6/2 (Fig. 8A) and HdhQ7/Q111 (Fig. 8B) mice showed
increased striatal levels of phosphorylated, inactive, STEP61. In con-
trast, pSTEP46 levels were increased in the striatum of R6/2 animals
(Fig. 8A) but remained unchanged in HdhQ7/Q111 mice (Fig. 8B).
These results indicate that the downregulation of STEP protein and
increased phosphorylation are found in the striatum of the three HD
mouse models analyzed. Moreover, these data support the
idea that the alteration of pSTEP46 levels occurs only at late
Figure7. Intrastriatal TAT–STEP injection increases QUIN-induced cell death in R6/1mice striatum. Control peptide (TAT–myc)
or TAT–STEP was intrastriatally injected in R6/1 mice 1 h before intrastriatal QUIN injection. A, Cell death was assessed by
Fluoro-Jade staining 24 h after QUIN injection. Representative photomicrographs show the striatal area occupied by Fluoro-Jade-
positive cells in R6/1 mice striatum injected with QUIN (a1), TAT–myc plus QUIN (a2), or TAT–STEP plus QUIN (a3). B, Immuno-
histochemical staining against pERK2 was performed 24 h after QUIN injection in R6/1 mice striatum with or without previous
injection of TAT–STEP. Representative images showing the striatum in all the conditions analyzed. In the inset, note the distinct
pERK2 immunoreactivity in non-injured (1) and injured (2) striatal cells. Scale bar, 500m.
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stages of the disease (30-week-old R6/1
and 12-week-old R6/2 mice versus
8-month-old Hdh Q7/Q111).
Changes in STEP expression are
reverted by suppressing the mhtt
transgene expression in Tet/HD94mice
striatum
To determine whether STEP downregula-
tion depends on the continuous expres-
sion of mhtt, we quantified STEP protein
levels in the striatum of Tet/HD94 mice.
Striatal STEP protein levels were exam-
ined in 22-month-old mice from three
different groups: wild-type, Tet/HD94
with no pharmacological intervention
(gene-ON), and Tet/HD94 after 5 months
of doxycycline administration that turns
off the expression of the mhtt transgene
(gene-OFF). As observed in the striatum
of the two other exon-1 models analyzed
here (R6/1 and R6/2) (Figs. 1, 8A, respec-
tively), STEP61 and STEP46 protein levels
were significantly decreased in the Tet/
HD94 gene-ON group when compared
with wild-type animals (Fig. 9A). By sup-
pressing transgene expression, STEP61
and STEP46 protein levels were no longer
different from wild-type mice (Fig. 9A).
We also determined the levels of
pSTEP61 and pSTEP46 in the striatum of
these mice. Tet/HD94 mice expressing
mhtt showed increased levels of pSTEP61
(Fig. 9B), but not of pSTEP46 (data not
shown), when compared with wild-type
values. In contrast to that observed for
STEP protein levels, 5 months after mhtt
shutdown pSTEP61 levels were only par-
tially reverted to wild-type levels (Fig. 9B).
Discussion
In the present study, we show that STEP
protein and activity are reduced in the
presence of mhtt in vivo. In the R6/1
mouse striatum, STEP hyperphosphory-
lation occurs early in the disease process
and correlates with a deregulation of the
PKA pathway, which at later stages coop-
erates with a reduction in calcineurin
activity to further inactivate STEP. Decreased STEP protein and
activity were also detected in the striatum of R6/2, Tet/HD94, and
Hdh Q7/Q111 mice. In addition, we show that STEP acts down-
stream of calcineurin after an excitotoxic stimulus and that inac-
tivation of STEP is one of the mechanisms involved in neuronal
dysfunction leading to resistance to excitotoxicity in R6/1 mice
striatum.
In the presence of mhtt, STEP is regulated at two different
levels, expression and phosphorylation, suggesting that both effects
could synergistically reduce STEP activity. The downregulation
of STEP protein is brain region specific as select combinations of
trans-acting factors and coactivators can contribute to both gene-
and tissue-specific effects of mhtt (Gomez et al., 2006). After mhtt
shutdown in Tet/HD94 mice striatum, we observed a reestablish-
ment of STEP protein to wild-type levels. This finding, together
with the fact that R6/1 mice develop motor symptoms at15–21
weeks of age (Mangiarini et al., 1996) and that STEP levels are
already decreased at 8 weeks of age, suggest altered transcription
of the STEP gene as a direct result of mhtt expression. However,
we cannot rule out that mhtt might also regulate STEP expression
by an indirect mechanism. In agreement with our results, a pre-
vious report showed that STEP mRNA levels are decreased to a
similar extent in 10- and 24-week-old R6/1 mice striatum (Des-
plats et al., 2006). Furthermore, STEP mRNA levels are also
decreased in the brain of HD patients (Hodges et al., 2006),
suggesting that reduced STEP expression could be involved in
the pathogenesis of HD.
STEP inactivation in R6/1 mice occurred in all brain regions
analyzed. The levels of pSTEP are regulated by PKA-dependent
Figure8. Alterations of STEP and pSTEP levels in the striatumof R6/2 andHdh Q7/Q111mice.A,B, pSTEP61, pSTEP46, STEP61, and
STEP46 levelswere analyzedbyWestern blot of protein extracts obtained from the striatumofWTandR6/2mice at 12weeks of age
(A) and from 8-month-old Hdh Q7/Q7 and knock-in Hdh Q7/Q111 mice (B). Representative immunoblots show the protein levels of
pSTEP61, pSTEP46, STEP61, STEP46, and-tubulin inWT, Hdh
Q7/Q7, R6/2, and Hdh Q7/Q111 mice. Values (obtained by densitometric
analysis of Western blot data) are expressed as percentage of WT/Hdh Q7/Q7 mice (pSTEP/STEP ratio after normalization with
-tubulin and STEP/-tubulin ratio, respectively) and shown asmean SEM (n 5–8). Datawere analyzed by Student’s t test.
*p 0.05 and ***p 0.001 compared with WT or Hdh Q7/Q7 mice, respectively.
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phosphorylation and calcineurin/PP1-dependent dephosphory-
lation (Paul et al., 2000, 2003; Valjent et al., 2005). Reduced cal-
cineurin levels in the striatum of R6/1 mice were observed from
16 weeks of age (Xifro´ et al., 2009), thus suggesting that changes
in pSTEP61 levels at early stages could be linked to a deregulation
of the PKA pathway. Accordingly, the phosphorylation level of
other PKA substrates, DARPP-32 (Thr34) (Hemmings et al.,
1984) and NR1 (Ser897) (Tingley et al., 1997), was significantly
increased in the striatum of R6/1 mice at 12 weeks of age. Simi-
larly, previous reports also showed increased striatal levels of
pNR1 (Ser897) in R6 mice at this age (Ariano et al., 2005; Torres-
Peraza et al., 2008). At later stages of the disease, the deregulation
of the PKA pathway is accompanied by a reduction in calcineurin
activity as evidenced by an even more robust elevation of pSTEP61
and pDARPP-32 (Thr34) levels, together with a significant in-
crease in pSTEP46 levels in the striatum of R6/1 mice.
STEP phosphorylation occurs after stimulation of D1Rs (Paul
et al., 2000), whose reduced expression is a hallmark of HD (Cha
et al., 1998; Jakel and Maragos, 2000; Ariano et al., 2002). How-
ever, despite D1R loss, D1R agonist-induced immediate early
genes mRNA levels are significantly increased in the striatum of
R6/2 mice, suggesting that mhtt may enhance the sensitivity of
D1R-mediated signaling (Spektor et al., 2002). Accordingly, D1R-
mediated toxicity is increased in HD cellular models (Tang et al.,
2007; Paoletti et al., 2008). In addition, enhanced levels of D5R
and elevations in intracellular cAMP staining have been shown in
the striatum of HD mouse models (Ariano et al., 2002, 2005). In
the presence of mhtt, parallel changes in other components of the
cAMP/PKA pathway, such as PDEs, can also be involved in a
PKA-dependent increase in pSTEP levels. Indeed, PDE10A ex-
pression, which is enriched in striatal projection neurons (Fu-
jishige et al., 1999; Seeger et al., 2003; Xie et al., 2006), is reduced
in R6 mice striatum (Hebb et al., 2004; Hu et al., 2004; Desplats et
al., 2006) and in the caudate–putamen of
HD patients (Hebb et al., 2004). Alto-
gether, these changes could cooperate to
enhance cAMP/PKA-dependent phos-
phorylation and inactivation of STEP.
The progressive inactivation of STEP
in the striatum of R6/1 mice correlated
with the accumulation of pERK2 and
p-p38 at late stages of the disease, consis-
tent with previous findings in R6 (Lie´vens
et al., 2002; Gianfriddo et al., 2004; Roze et
al., 2008; Torres-Peraza et al., 2008) and
STEP knock-out (Venkitaramani et al.,
2009; Xu et al., 2009) mice. The absence of
changes in pERK2 and p-p38 levels at
early stages suggests that, under baseline
conditions, a high inactivation of STEP is
necessary to impact on the phosphoryla-
tion level of its targets. Accordingly, both
in vitro and in vivo studies show that STEP
activity is low under basal conditions
(Paul et al., 2003; Valjent et al., 2005).
Moreover, hippocampal pERK1/2 levels
are increased in STEP knock-out but not
in STEP/ mice (Venkitaramani et al.,
2009). However, we cannot rule out that
the presence of mhtt may also affect
mechanisms activating ERK and p38. Ac-
tivation of the ERK pathway is neuropro-
tective in multiple HD models (Apostol et
al., 2006; Maher et al., 2011). Thus, despite higher p-p38 levels
(Gianfriddo et al., 2004; present results), increased ERK signaling
in the striatum of R6/1 (present results) and R6/2 (Lie´vens et al.,
2002; Roze et al., 2008) mice, in addition to high levels of activa-
tion of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
(Saavedra et al., 2010), could participate in delaying striatal cell
death because R6 mice show no significant cell loss (Mangiarini et
al., 1996).
The development of resistance to NMDAR-induced excito-
toxicity in R6/1 mice raises the possibility that the activation of
intracellular pathways after NMDAR stimulation might be dif-
ferentially regulated in the presence of mhtt. Actually, activation
of the PI3K/Akt pathway may participate in the reduced neuronal
loss observed after QUIN injection in R6/1 mice striatum (Saave-
dra et al., 2010). Here, we show higher and unaltered pSTEP
levels after intrastriatal QUIN injection in R6/1 consistent with
lower calcineurin activation than in wild-type mice, which, im-
portantly, correlates with reduced cell death (Xifro´ et al., 2009)
and more sustained ERK signaling. Activation of extrasynaptic
NMDARs in primary cortical neurons leads to calpain-mediated
proteolysis of STEP61 and p38 activation (Xu et al., 2009). Here,
we observed STEP dephosphorylation but not STEP61 cleavage or
p38 activation after intrastriatal QUIN injection, which, together
with ERK2 activation, suggests a preferential stimulation of syn-
aptic NMDARs. YAC128 mice show an imbalance between syn-
aptic and extrasynaptic NMDARs (Okamoto et al., 2009;
Milnerwood et al., 2010). However, these mice develop resistance
to excitotoxicity with age (Graham et al., 2009), and those studies
were performed in vulnerable mice. Thus, it is likely that in-
creased extrasynaptic NMDARs during excitotoxicity-sensitive
stages might increase STEP61 cleavage to STEP33, enabling higher
activation of p38 than in wild-type mice. In contrast, in resistant
mice other mechanisms should regulate striatal cell survival in
Figure 9. Changes in STEP expression but not in STEP phosphorylation are reverted by suppressing themhtt transgene expres-
sion in Tet/HD94 mice striatum. pSTEP61, STEP61, and STEP46 protein levels were analyzed by Western blot in the striatum of
22-month-oldWTandTet/HD94mice, eitherwithnopharmacological intervention (Gene-ON)or after 5monthsofmhtt transgene
shutdown by doxycycline administration (Gene-OFF). A, B, The graphs show the densitometric measures of STEP61 and STEP46
normalized to-tubulin (A) and the pSTEP61/STEP ratio after normalizationwith-tubulin (B). Results are expressed as percent-
ages ofWT SEM. Datawere analyzed by one-way ANOVA, followed by Bonferroni’s post hoc test. *p 0.05 comparedwithWT
mice; #p 0.05 compared with Tet/HD94 gene-ONmice.
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response to excitotoxicity, and the present results suggest an im-
portant role for STEP regulation of ERK activity. Accumulating
evidence shows that increases in ERK activity are neuroprotective
(Irving et al., 2000; Almeida et al., 2005; Jiang et al., 2005; Choi et
al., 2007). In agreement, pharmacological inhibition of calcineu-
rin or PDE10A, which leads to decreased STEP activity with sub-
sequent increase in pERK2 levels (present results), is protective
against QUIN-induced excitotoxicity in the striatum (Giampa` et
al., 2009; Xifro´ et al., 2009). In addition, a higher level of tonic
STEP activity in hilar interneurons of the hippocampus renders
them highly vulnerable to excitotoxic-induced cell death,
whereas blockade of STEP activity with FK-506 allows ERK acti-
vation and confers protection against excitotoxicity (Choi et al.,
2007). Therefore, our results showing low striatal STEP levels and
activity (increased pSTEP levels) in R6/1 mice are in agreement
with their reduced vulnerability to excitotoxicity. This hypothesis
is supported by the observation that TAT–STEP infusion in-
creases QUIN-induced cell death in the striatum.
In conclusion, we show that mhtt regulates STEP expres-
sion in selected brain regions and exerts a broader effect on the
regulation of STEP phosphorylation. Increased STEP phosphor-
ylation caused by altered kinase (PKA) and phosphatase (cal-
cineurin) activities may lead to neuronal dysfunction and
participate in the development of resistance to excitotoxicity in
HD mouse models (supplemental Fig. 4, available at www.
jneurosci.org as supplemental material). Although alterations in
the STEP pathway occur in other neurodegenerative conditions,
such as Alzheimer’s disease (AD), changes described here are
specific to HD because STEP protein levels and activity are ele-
vated in AD (Chin et al., 2005; Kurup et al., 2010; Zhang et al.,
2010), whereas PKA activity is reduced (Gong et al., 2006) and
calcineurin activity is enhanced (Kuchibhotla et al., 2008). Be-
cause genetic reduction of STEP levels reverses cognitive and
cellular deficits in AD mice (Zhang et al., 2010), the modulation
of STEP levels might be a good therapeutic strategy. However,
given the lack of data about the regulation of STEP gene expres-
sion, we cannot propose a therapeutic approach to restore STEP
expression in HD. Therefore, we suggest that modulation of the
PKA activity could be a therapeutic approach, at least at early
stages.
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